ArticlePeerJ2026
A retrospective quantitative CT study reveals subclinical pulmonary vascular loss and right middle lobe vulnerability in PM/DM patients without interstitial lung disease.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High-resolution computed tomography assessment of connective tissue disease-associated interstitial lung disease: Advances in diagnosis and prognostic evaluation.World journal of radiology · 2026Review
- Bibliometric Analysis of Pulmonary Fibrosis Imaging Research: Knowledge Graph Construction Based on the Web of Science Core Database.Malawi medical journal : the journal of Medical Association of Malawi · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Connective tissue disease-associated interstitial lung disease (CTD-ILD) is triggered by pulmonary vascular injury. However, early subclinical lung changes in polymyositis/dermatomyositis (PM/DM) patients without ILD (PM/DM-non-ILD) remain undetectable by conventional imaging. Objective: To evaluate microvascular integrity and parenchymal features in PM/DM-non-ILD patients using quantitative computed tomography (QCT). Additionally, this study aims to identify associations between QCT parameters and laboratory markers of inflammation and autoimmunity, and evaluate the performance of QCT metrics in detecting subclinical lung pathology. Method: This retrospective study included 71 PM/DM-non-ILD patients and 71 age- and sex-matched healthy controls were enrolled. Chest high-resolution CT (HRCT) images, laboratory data, and clinical records were collected. All HRCT scans were analyzed using the "Digital Lung" platform to obtain QCT parameters, including lung volume, density, and intrapulmonary vascular volumes (IPVV) for the whole lung and individual lobes. Standardized IPVV was calculated by dividing the vascular volume by the corresponding lobe volume to account for lung volume differences. QCT parameters and laboratory results were compared, their correlation analyzed, and diagnostic performance evaluated using receiver operating characteristic (ROC) analysis. Results: In PM/DM-non-ILD patients, standardized IPVV was notably lower in the entire lung and each lobe compared to healthy controls ( Conclusion: The decreased standardized intrapulmonary vascular volume (IPVV), across all lung lobes (whole lung, right lung, left lung, right upper lobe, right middle lobe, right lower lobe, left upper lobe, left lower lobe) indicates its potential as a sensitive marker for early pulmonary involvement in patients with polymyositis/dermatomyositis without interstitial lung disease. The distinct vascular changes in the right middle lung lobe may serve as a discriminative indicator for subclinical lung pathology in this population, potentially reflecting underlying immune dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.